20.49
+2.91%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Viatris
From its filings with the US Securities and Exchange Commission
Viatris is based in Canonsburg, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker VTRS. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $14.30bn and a net loss of $3.51bn. At that date it held total assets of $37.19bn and shareholders' equity of $14.71bn.
Viatris is a global healthcare company whose breadth and scale we believe make it uniquely positioned to address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, Viatris supplies high-quality medicines to approximately 1 billion patients around the world each year. The Company has a global footprint, an extensive portfolio of medicines that is well-diversified across therapeutic areas, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges.
Viatris’ executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders. The Company operates in more than 165 countries and territories with more than 30,000 employees. The Company has 27 manufacturing, packaging, and distribution sites worldwide, more than 1,400 approved molecules, and what we believe is industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise. Viatris’ portfolio consists of generics (including complex products), globally recognized iconic brands, and an expanding portfolio of innovative medicines. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Nov 2020
- Employees
- 30,000
- Website
- viatris.com ↗
- Head office
- 1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Melina HigginsIndependent Non-Executive Chairman of the Board$670,001
- Mr. Scott SmithChief Executive Officer, Director, since 2022$14.8m
- Mr. Mark ParrishIndependent Vice Chairman of the Board$475,001
- Ms. Theodora MistrasChief Financial Officer$6.4m
- Mr. Paul CampbellChief Accounting Officer, Corporate Controller$5.5m
- Mr. Andrew EnriettiChief Administrative and Transformation Officer
- Dr. Corinne Le GoffChief Commercial Officer$5.9m
- Mr. Brian RomanChief Legal Officer$4.7m
- Mr. Hemanth VargheseChief Strategy Officer
- Mr. Rajiv MalikDirector, since 2020$375,787
- Mr. Rogerio CoelhoIndependent Director$311,480
- Mr. Wyllie CornwellIndependent Director$395,001
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 66
- Social
- 83
- Governance
- 47
- Direct emissions (scope 1)
- 334,041 t
- Energy emissions (scope 2)
- 477,974 t
- Value chain emissions (scope 3)
- 2,317,978.25 t
- Women in the workforce
- 36.4%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Viatris Inc has a strong global presence with operations and distribution channels across multiple countries. This provides the company with access to diverse markets, enabling it to reach a wider customer base.
- Viatris Inc offers a diverse range of pharmaceutical products covering various therapeutic areas, including generics and specialty drugs. This extensive portfolio allows the company to cater to different patient needs and capture market share in multiple segments.
Weaknesses
- Viatris Inc relies heavily on external suppliers for raw materials and active pharmaceutical ingredients. Any disruptions or quality issues in the supply chain can significantly impact the company's manufacturing capabilities and affect its overall business operations.
- The pharmaceutical industry is highly competitive, and Viatris Inc faces intense competition from both established players and emerging companies. This competitive landscape increases the pressure on the company to continuously innovate, differentiate its products, and maintain market share.
Opportunities
- Viatris Inc has the opportunity to expand its presence in emerging markets, where the demand for affordable medications is increasing. By targeting these markets and adapting its products to meet local needs, the company can tap into new revenue streams and achieve long-term growth.
- The rapid advancements in biotechnology and specialty drugs present an opportunity for Viatris Inc to develop and commercialize innovative treatment options. By investing in research and development, the company can introduce novel therapies addressing unmet medical needs and gain a competitive edge.
Threats
- The pharmaceutical industry is subject to stringent regulations and increasing scrutiny from regulatory authorities. Viatris Inc needs to ensure compliance with these regulations, which may involve additional costs, legal complexities, and potential delays in product approvals.
- Price fluctuations in raw materials and intense pricing pressure in the pharmaceutical market pose threats to Viatris Inc's profitability. The company needs to actively manage cost structures, negotiate favorable pricing agreements, and explore value-added services to mitigate these threats.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.